Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 9.21 USD -0.22% Market Closed
Market Cap: 2.8B USD

Amicus Therapeutics Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amicus Therapeutics Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Amicus Therapeutics Inc
NASDAQ:FOLD
Inventory
$115.3m
CAGR 3-Years
73%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Inventory
$4.5B
CAGR 3-Years
13%
CAGR 5-Years
18%
CAGR 10-Years
16%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$3.4B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Inventory
$7.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.1B
CAGR 3-Years
48%
CAGR 5-Years
46%
CAGR 10-Years
51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$3B
CAGR 3-Years
14%
CAGR 5-Years
18%
CAGR 10-Years
38%

Amicus Therapeutics Inc
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

In the ever-evolving landscape of biotech, Amicus Therapeutics Inc. stands as a beacon of innovation, rooted deeply in the realm of rare and orphan diseases. Founded with the mission to harness advanced therapies for conditions with limited treatment options, the company has carved a niche in developing treatments that hinge on cutting-edge science. Specifically, Amicus focuses on creating next-generation therapies involving chaperone proteins and genetic medicines. These specialized therapies work by stabilizing and enhancing the function of faulty proteins that are hallmarks of many genetic disorders, thereby directly addressing the underlying causes of these conditions. Their portfolio, prominently featuring Galafold (migalastat) for Fabry disease, exemplifies their approach—leveraging precision medicine to cater to patients who have been underserved by traditional pharmaceutical models. Revenue generation for Amicus Therapeutics predominantly revolves around the commercialization of Galafold, which is approved in numerous global markets. Galafold offers a personalized approach, being targeted towards individuals with Fabry disease who possess amenable genetic mutations. This specificity not only underscores Amicus's commitment to precision therapeutics but also reinforces its competitive edge, as the treatment reduces the necessity for enzymatic replacement, a conventional route with broader systemic impacts. Beyond its current offerings, Amicus is strategically investing in its pipeline of gene therapies, aiming to provide breakthroughs in conditions like Pompe disease and other rare metabolic disorders. By enhancing existing therapies and fostering new breakthroughs, Amicus not only upholds its commitment to patient-centric solutions but also bolsters its financial sustainability through strategic innovation and market expansion.

FOLD Intrinsic Value
13.4 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Amicus Therapeutics Inc's Inventory?
Inventory
115.3m USD

Based on the financial report for Sep 30, 2024, Amicus Therapeutics Inc's Inventory amounts to 115.3m USD.

What is Amicus Therapeutics Inc's Inventory growth rate?
Inventory CAGR 5Y
66%

Over the last year, the Inventory growth was 103%. The average annual Inventory growth rates for Amicus Therapeutics Inc have been 73% over the past three years , 66% over the past five years .

Back to Top